

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/788,188	02/16/2001	Mark Tuszynski	041673/2045	5329
75	590 09/10/2002			
Stacy L. Taylor FOLEY & LARDNER 402 West Broadway, 23rd Floor			EXAMINER	
			CHEN, SHIN LIN	
San Diego, CA 92101-3542			ART UNIT	PAPER NUMBER
			1632	a
		DATE MAILED: 09/10/2002	9	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Action Summers	09/788,188	TUSZYNSKI ET AL.			
Office Action Summary	Examiner	Art Unit			
TI. MAII INO DATE Au	Shin-Lin Chen	1633			
Th MAILING DATE of this communication appears on the cover she t with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on					
2a) This action is FINAL . 2b) Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4) Claim(s) 1-25 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-25</u> are subject to restriction and/or election requirement. Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accep	ted or b)⊡ objected to by the Exar	miner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)			
C. D. C. T. L. C. C.					

Art Unit: 1633

DETAILED ACTION

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-10, drawn to a mutant pro-neurotrophin protein that has an asparagine residue at a position 8 or 4 amino acids upstream from the site of cleavage for the mature growth factor, classified in class 530, subclass 350.
 - II. Claims 11-25, drawn to a polynucleotide encoding a mutant pro-neurotrophin, a recombinant expression vector containing said polynucleotide, a host cell containing said expression vector, a pharmaceutical composition containing the expression vector or host cell, and a process for producing a mutant proneurotrophin by using said polynucleotide, classifiable in classes 536 and 435, subclasses 23.51 and 325, 69.1, respectively.
- 2. The inventions are distinct, each from the other because of the following reasons:

Groups I and II are distinct from each other because they are drawn to compositions having different chemical structure, physical properties and biological functions and requiring separate search: protein and polynucleotide. Search for polynucleotide does not require search for polypeptide. Since the classification for each is different, the search for each group would not be coextensive. They are not obvious variants and deemed patentably distinct.

Upon election of a group, a further restriction (**not** a selection of species) is required as follows:

Application/Control Number: 09/788,188 Page 3

Art Unit: 1633

Since the SEQ ID Nos recited in the claims of the present application represent different and distinct DNA sequences derived from different genes. The chemical structures of different genes are different from each other and their gene product functions also differ from each other. Thus, the SEQ ID Nos recited in the claims of the present application are patentably distinct from each other and require separate search. Applicant is required to elect a **single** SEQ ID No. or

Group I: SEQ ID Nos. 1, 3, 5, 7.

Group II: SEQ ID Nos. 9 and 16, 10-13.

sequence from a single gene as followed for consideration by examiner:

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Application/Control Number: 09/788,188 Page 4

Art Unit: 1633

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (703) 305-1678. The examiner can normally be reached on Monday to Friday from 9 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Scott Priebe can be reached on (703) 308-7310. The fax phone number for this group is (703) 308-4242.

Questions of formal matters can be directed to the patent analyst, Patsy Zimmerman, whose telephone number is (703) 305-2758.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Shin-Lin Chen, Ph.D.

4 Mher